Obsessive compulsive symptoms in psychotic disorders

Swets, M.

Citation for published version (APA):
Obsessive-Compulsive Symptoms in patients with schizophrenia comparing treatment with Clozapine, Olanzapine, Risperidone and no antipsychotics: a naturalistic cross-sectional study of 543 patients

Albertine A. Scheltema Beduin MD, Marije Swets MD, Marise Machielsen MD, Nikie Korver MsC and GROUP investigators*

*René S. Kahn MD, PhD, Don H. Linszen MD, PhD, Jim van Os MD, PhD, Durk Wiersma MD, PhD, Richard Bruggeman MD, PhD, Wiepke Cahn MD, PhD, Lieuwe de Haan MD, PhD, Lydia Krabbendam MD, PhD, Inez Myin-Germey MS, PhD

J Clin Psychiatry 73:11 November 2012; 1395-1402
ABSTRACT

Objective:
We aim to compare the prevalence of obsessive-compulsive symptoms (OCS) in a population of patients with schizophrenia taking clozapine, olanzapine or risperidone or taking no antipsychotic medication.

Methods:
Baseline data of the Genetic Risk and Outcome of Psychosis study were collected between April 2005 and October 2008. We conducted a naturalistic cross-sectional study of 543 patients with schizophrenia and related disorders, meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, taking no antipsychotic medication, taking clozapine, olanzapine or risperidone. OCS severity was measured with the Yale-Brown Obsessive Compulsive Scale. We compared patients to a sample of 575 healthy controls.

Results:
Prevalence of OCS in patients was significantly higher than in the control sample, 23.4% versus 4.9% ($X^2=73.8$, $p<.001$). Patients taking clozapine reported significantly more often OCS during the last week (38.9%), when compared to patients taking olanzapine (20.1%, $X^2=10.02$, $p=.002$), risperidone (23.2%, $X^2=5.96$, $p=.015$) and patients not taking antipsychotics (19.6%, $X^2=8.20$, $p=.004$). When patients took clozapine for more than 6 months they reported OCS significantly more often than patients taking clozapine for less than 6 months, 47.3% versus 11.8% ($X^2=6.89$, $p=.009$).

Conclusion:
Treatment with clozapine in patients with schizophrenia is associated with a higher prevalence of OCS, especially when patients have been taking clozapine for 6 months or longer. We cannot rule out the possibility that this association is related to illness characteristics. Patients treated with risperidone, olanzapine or without treatment with antipsychotic medication had comparable prevalence of OCS, significantly higher than the control sample.

Keywords: schizophrenia, obsessive-compulsive symptoms, clozapine, olanzapine, risperidone
INTRODUCTION

A substantial proportion of patients with schizophrenia have comorbid obsessive compulsive symptoms (OCS) and obsessive-compulsive disorder (OCD). The prevalence of OCS and OCD in patients with schizophrenia is estimated, respectively, 25 to 64% and 7.8 to 30%. In a recent meta-analysis Swets et al. found pooled prevalence rates of 30.0% and 12.3% for OCS and OCD respectively (Swets et al., unpublished data, 2012). This is remarkably higher than expected, considering the lifetime prevalence of OCS 21-25% and OCD 0.3-3% in the general population. Moreover recent studies report a worse outcome in patients with schizophrenia and OCS or OCD.

There is an ongoing debate regarding the reasons for these high comorbidity rates. Some postulate the existence of a distinct schizo-obsessive subtype of schizophrenia, but conclusive proof is lacking. Several authors suggest that a substantial part of the OCS-comorbidity is related to the use of specific atypical antipsychotics. The emergence or deterioration of OCS have predominantly been reported during use of clozapine and risperidone and has been associated with use of olanzapine as well. Clozapine is thought to have the highest propensity for the emergence or deterioration of OCS on the basis of its antiserotonergic properties. This hypothesis is supported by the efficacy of SSRI’s in the treatment of clozapine-induced OCS.

On the other hand atypical antipsychotics represent an effective treatment of OCD-patients and in some psychotic patients with comorbid OCS they are reported to alleviate the OCS-symptoms.

Duration of treatment with antipsychotics is possibly a contributing factor in the emergence or deterioration of OCS, with a longer duration of treatment associated with more OCS.

The best way to study the hypothesis that specific antipsychotics induce or worsen OCS is to compare the effects of these compounds in a double-blind randomized controlled design. Only 2 such studies are available. One study reports that olanzapine did not cause OCS when compared to placebo. A more recent double-blind randomized controlled study compared olanzapine to risperidone in 122 patients with early psychosis. A significant decrease in OCS after 6 weeks of treatment favouring olanzapine was found. However, illustrating the response complexity, after 6 weeks of treatment in 2 patients taking olanzapine and 8 patients taking risperidone de novo OCS occurred. We are not aware of double-blind randomized studies on the effect of clozapine on OCS.

Placebo controlled trials to ascertain whether OCS occurs more often during treatment with antipsychotic medication than without are not feasible on ethical grounds. Furthermore patients who are able and willing to be included in a randomized double-blind medication study may not be representative of the general patient population. Therefore other research strategies will have to contribute to our knowledge on the relation between antipsychotic treatment and OCS in patients with psychotic disorders.
In the present study we aimed to compare the prevalence of OCS in a large population of patients with schizophrenia taking no antipsychotic medication or taking clozapine, olanzapine or risperidone. We chose to compare these atypical antipsychotics because these agents have been associated with emergence or deterioration of OCS in several publications.  

We hypothesize that patients treated with the atypical antipsychotics clozapine, olanzapine and risperidone would have a higher prevalence of comorbid OCS compared to patients not taking antipsychotic medication. Because of its specific dopaminergic and serotonergic profile we expect clozapine to be associated with the highest prevalence of OCS. We expect patients not treated with antipsychotics to have a higher prevalence of OCS than healthy controls. We expect that a longer duration of treatment would be associated with a higher prevalence of OCS.

**METHODS**

**Participants**

The study sample was taken from the baseline data of 1120 patients who were examined within the Genetic Risk and Outcome of Psychosis (GROUP) study. Data was collected between April 2005 and October 2008. In summary, GROUP is a multisite, longitudinal, naturalistic cohort study examining the 6 year course of patients with non-affective psychotic disorders and their siblings. Patients were recruited from mental health centres covering more than 75% of the mental health institutions of the Netherlands, including both inpatient and outpatient clinics. Eligible patients for the GROUP project had to fulfil the following criteria: (1) age between 16 and 50, (2) meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (American Psychiatric Association 1994) criteria for a non-affective psychotic disorder (schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, psychotic disorder NOS) (3), fluent in Dutch, and (4) able and willing to give written informed consent. Persons identified as potentially eligible were given detailed explanation of the study procedures and were asked for informed consent for detailed assessment and for contacting their first-degree family members (brothers, sisters, parents).

Inclusion criteria for siblings were the following: (1) age range of 16 to 50, (2) fluent in Dutch, (3) able and willing to give written informed consent. Comorbidity in patients, siblings and parents was not an exclusion criterion. When siblings or parents appeared to have a lifetime psychotic disorder they were included in the patient group.

Controls were selected through a system of random mailings to addresses in the catchment areas of the cases. Inclusion criteria for healthy controls were the following: (1) age range of 16 and 50, (2) having no lifetime psychotic disorder, (3) having no first-degree family member with a lifetime psychotic disorder, (4) fluent in Dutch, and (5) able and willing to give written informed consent.
Obsessive-Compulsive Symptoms in patients with schizophrenia comparing treatment with Clozapine, Olanzapine, Risperidone and no antipsychotics: a naturalistic cross-sectional study of 543 patients

The study protocol was approved centrally by the Ethical Review Board of the University Medical Centre Utrecht and subsequently by local review boards of each participating institute. After full verbal and written information about the study, informed consent was obtained from all participants before the start of the first assessment. Healthy volunteers were recruited by advertisements and by mailings. (For more detailed information about the GROUP project see Korver et al.).

For the current report we included patients with schizophrenia or related disorders of whom data on OCS (assessed with the Yale-Brown Obsessive Compulsive Scale [Y-BOCS]) were available. We compared patients treated with clozapine, olanzapine, risperidone or taking no antipsychotic medication to a sample of healthy controls. We excluded patients who used more than 1 type of antipsychotic medication.

Instruments

**Comprehensive Assessment of Symptoms and History/Schedules for Clinical Assessment for Neuropsychiatry.** To establish a DSM-IV diagnosis of psychotic disorder, the Comprehensive Assessment of Symptoms and History (CASH) or the Schedules for Clinical Assessment for Neuropsychiatry (SCAN 2.1) was used.

**Y-BOCS.** First the presence of obsessive and compulsive symptoms during the week before assessment was assessed, defined according to the Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P), as persistent, repetitive, intrusive, and distressful thoughts (obsessions) not related to the patient’s delusions, or repetitive goal-directed rituals (compulsions) clinically distinguishable from schizophrenic mannerisms or posturing. To measure the severity of obsessive and compulsive symptoms the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) was used. The scale measures 5 obsessive-compulsive aspects (duration, interference, distress, resistance and control) as reported by the subject and is divided into an obsessions subscale and a compulsions subscale. Previous research has found the Y-BOCS suitable for assessing severity of obsessive-compulsive symptoms in patients with schizophrenia. When the Y-BOCS score was positive, the presence of OCS was established.

Table 1. Demographics and Disease Characteristics of Patients, Siblings, and Controls

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Patients (n=543)</th>
<th>Siblings (n=979)</th>
<th>Test statistics</th>
<th>P Value</th>
<th>Controls (n=575)</th>
<th>Test Statistics</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y</td>
<td>27.6 (7.59)</td>
<td>27.8 (8.33)</td>
<td>z = -0.07</td>
<td>.95</td>
<td>30.4 (10.63)</td>
<td>z = -3.02</td>
<td>.003</td>
</tr>
<tr>
<td>Sex, male, %</td>
<td>79.0</td>
<td>46.1</td>
<td>Χ² = 155.4</td>
<td>&lt;.001</td>
<td>45.4</td>
<td>Χ² = 133.6</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Ethnicity, white, %</td>
<td>78.3</td>
<td>82.9</td>
<td>Χ² = 5.01</td>
<td>.03</td>
<td>90.3</td>
<td>Χ² = 48.37</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>OCS last week, %</td>
<td>24.9</td>
<td>7.8</td>
<td>Χ² = 73.8</td>
<td>&lt;.001</td>
<td>4.9</td>
<td>Χ² = 72.85</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

Abbreviations: OCS = obsessive-compulsive symptoms, SD = standard deviation.
Table 2. Demographics and Disease Characteristics of Patients Treated With Clozapine, Olanzapine, Risperidone, or No Antipsychotic Medication, With or Without Obsessive-Compulsive Symptoms (OCS) During the Last Week

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Patients With OCS During Last Week</th>
<th>Patients Without OCS During Last Week</th>
<th>Test statistics</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n=135, 24.9%)</td>
<td>(n=408, 75.1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, mean (SD), y</td>
<td>27.2 (7.23)</td>
<td>27.8 (7.70)</td>
<td>z = -0.377</td>
<td>.706</td>
</tr>
<tr>
<td>Sex, male, %</td>
<td>80.7</td>
<td>78.4</td>
<td>X^2 = .326</td>
<td>.507</td>
</tr>
<tr>
<td>Ethnicity, white, %</td>
<td>75.6</td>
<td>78.3</td>
<td>X^2 = 1.2</td>
<td>.179</td>
</tr>
<tr>
<td>OCS last week, %</td>
<td>21.1 (7.07)</td>
<td>23.3 (6.89)</td>
<td>z = -3.07</td>
<td>.002</td>
</tr>
<tr>
<td>Duration of illness, mean(SD), y</td>
<td>5.59 (5.25)</td>
<td>3.94 (3.94)</td>
<td>z = -4.00</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Abbreviations: SD = standard deviation.

**The positive and Negative Syndrome Scale.** The Positive and Negative Syndrome Scale (PANSS) is currently the most widely used scale to assess a variety of symptoms in patients with schizophrenia. It consists of 30 items, each item ranging on a 7 point scale of severity from 1 (absent) to 7 (extreme). Originally, the PANSS consisted of 3 subscales: positive syndrome scale (items P1-P7), a negative syndrome scale (items N1-N7), and a general psychopathology scale (items G1-G16). Peralta and Cuesta showed that the positive and negative subscale can be better conceptualized as composed of 3 factors instead of 2 factors: positive, disorganized, and negative.

**Statistical analysis**

Statistical analyses were performed using SPSS 18.0.2 software (IBM, Armonk, New York). Demographics and disease characteristics were compared between patients and controls using Pearson χ^2 tests, and when assumption of normal distribution was violated, Mann-Whitney U tests were used. Of the patients with OCS, demographic and disease characteristics were compared in the different medication groups using Pearson χ^2 tests and, when the assumption of normal distribution was violated, Kruskal-Wallis tests. Y-BOCS scores were compared between the different medication groups using 1-way analysis of variance (ANOVA). Logistic regression was used to compare groups, controlling for confounding variables.
RESULTS

The GROUP-sample consisted of 1,120 patients, 1,057 siblings and 590 healthy controls. Of the patients, data on OCS prevalence and severity were available for 107 patients not taking antipsychotics and 431 patients taking clozapine (n=71), olanzapine (n=196) or risperidone (n=149). Data on OCS prevalence and severity were available for 979 siblings and for 575 controls.

Prevalence of OCS in the sample of 543 patients (23.4%) was significantly higher than in the group of 979 siblings (7.8% $\chi^2=73.8$, p<.001) and 575 healthy controls, (4.9% $\chi^2=80.2$, p<.001; Table 1). The difference in the prevalence of OCS between siblings and controls, 7.8% versus 4.9%, respectively ($\chi^2=4.9$, p=.032), was much smaller, but significant. The control sample was significantly different from the patient sample concerning sex, age and ethnicity. The sibling sample differed significantly from the patient sample when sex was considered (see Table 1). Differences in prevalence between controls and patients remained highly significant, even after controlling for sex, age, and ethnicity using logistic regression analysis, with an unadjusted odds ratio (OR) of 5.90 (95% confidence interval [CI],3.89-9.16) and an adjusted OR of 5.74 (95% CI,3.70-8.95), with none of the possible confounders reaching statistical significance.

Comparing patients with and without OCS, no differences were found in sex, age and ethnicity. Patients with OCS had a significantly earlier age of onset of psychosis (Z=-3.07, p=.002) and had a significantly longer duration of illness (Z=-4.00, p<.001) (Table 2).

Comparing the prevalence of OCS between the different medication groups revealed a significant difference ($\chi^2=11.77$, p=.008). Post-hoc tests showed that patients taking clozapine reported significantly more OCS during the last week (38.9%), when compared to patients taking olanzapine (20.1%, $\chi^2=10.02$, p=.002), risperidone (23.2%, $\chi^2=5.96$, p=.015) and patients not taking antipsychotics (19.6%, $\chi^2=8.20$, p=.004). Comparing diagnoses between patients using antipsychotics versus patients not using antipsychotics, no significant difference was found. 77.7% were diagnosed with schizophrenia versus 67.0% of those not using antipsychotics ($\chi^2=6.73$, p=.150). The remaining diagnoses of patients taking antipsychotics versus patients not taking antipsychotics were respectively, schizoaffective disorder 9.0% versus 11.6%; brief psychotic disorder or psychosis not otherwise specified 10.0% versus 15.2%; delusional disorder 1.9% versus 2.7%; and other psychotic disorders 1.4% versus 3.6%.
Table 3. Demographics and Disease Characteristics of Patients Treated With Clozapine, Olanzapine, Risperidone, or No Antipsychotic Medication, With Obsessive-Compulsive Symptoms (OCS) During the Last Week

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Clozapine (n=28, 22.0%)</th>
<th>Olanzapine (n=41, 32.3%)</th>
<th>Risperidone (n=36, 28.3%)</th>
<th>No Antipsychotics (n=22, 17.3%)</th>
<th>X²</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y</td>
<td>27.4 (3.81)</td>
<td>25.9 (6.08)</td>
<td>27.5 (8.63)</td>
<td>29.1 (9.65)</td>
<td>3.90</td>
<td>.273</td>
</tr>
<tr>
<td>Sex, male, %</td>
<td>89.3</td>
<td>80.5</td>
<td>86.1</td>
<td>63.6</td>
<td>6.20</td>
<td>.102</td>
</tr>
<tr>
<td>Ethnicity, white, %</td>
<td>67.9</td>
<td>82.9</td>
<td>75.0</td>
<td>68.2</td>
<td>2.67</td>
<td>.446</td>
</tr>
<tr>
<td>Age at onset of first psychosis, mean (SD), y</td>
<td>19.3 (4.55)</td>
<td>21.1 (5.53)</td>
<td>21.1 (7.89)</td>
<td>23.5 (10.50)</td>
<td>2.34</td>
<td>.506</td>
</tr>
<tr>
<td>Duration of illness, mean(SD), y</td>
<td>7.69 (3.45)</td>
<td>4.24 (3.90)</td>
<td>5.87 (7.42)</td>
<td>5.01 (4.42)</td>
<td>17.91</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Daily dose of antipsychotics, mean (SD), mg</td>
<td>357.1 (160.85)</td>
<td>14.2 (5.83)</td>
<td>5.4 (9.45)</td>
<td>NA</td>
<td>NA</td>
<td>NS</td>
</tr>
</tbody>
</table>

Abbreviations: VA = Not applicable, SD = standard deviation.

Table 4. Prevalence of OCS in Odds Ratios (ORs) Comparing Patients Using No Antipsychotics, Risperidone, Olanzapine, Clozapine < 6 Months, and Clozapine ≥ 6 Months

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Clozapine &lt;6months (n=17, 23.6%)</th>
<th>Clozapine ≥ 6months (n=55, 76.4%)</th>
<th>Test statistics</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y</td>
<td>29.3 (6.71)</td>
<td>26.0 (4.06)</td>
<td>z = -1.56</td>
<td>.118</td>
</tr>
<tr>
<td>Sex, male, %</td>
<td>100</td>
<td>85.5</td>
<td>χ² = 2.78</td>
<td>.095</td>
</tr>
<tr>
<td>Ethnicity, white, %</td>
<td>82.4</td>
<td>60.0</td>
<td>χ² = 2.86</td>
<td>.091</td>
</tr>
<tr>
<td>Age at onset of first psychosis, mean (SD), y</td>
<td>25.0 (6.37)</td>
<td>18.8 (3.84)</td>
<td>z = -3.73</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Duration of illness, mean(SD), y</td>
<td>3.81 (3.18)</td>
<td>6.73 (3.07)</td>
<td>t = -3.24</td>
<td>.001</td>
</tr>
<tr>
<td>Daily dose of antipsychotics, mean (SD), mg</td>
<td>341.2 (199.2)</td>
<td>304.1 (146.2)</td>
<td>χ² = -0.882</td>
<td>.378</td>
</tr>
<tr>
<td>OCS last week, %</td>
<td>11.8</td>
<td>47.3</td>
<td>χ² = 6.89</td>
<td>.009</td>
</tr>
</tbody>
</table>

Abbreviations: OCS = obsessive-compulsive symptoms, SD = standard deviation.
Obsessive-Compulsive Symptoms in patients with schizophrenia comparing treatment with Clozapine, Olanzapine, Risperidone and no antipsychotics: a naturalistic cross-sectional study of 543 patients

Table 5. Demographics and Disease Characteristics of Patients Treated With Clozapine for 6 Months or Longer or Less Than 6 Months

<table>
<thead>
<tr>
<th>Variable</th>
<th>Unadjusted Model OR (95% CI)</th>
<th>Fully adjusted Model OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No antipsychotic use (n=107)</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Risperidone (n=149)</td>
<td>1.3 (0.7-2.3)</td>
<td>1.3 (0.7-2.4)</td>
</tr>
<tr>
<td>Olanzapine (n=196)</td>
<td>1.1 (0.6-2.0)</td>
<td>1.2 (0.6-2.1)</td>
</tr>
<tr>
<td>Clozapine &lt; 6 months (n=16)</td>
<td>0.3 (0.03-2.2)</td>
<td>0.2 (0.003-1.9)</td>
</tr>
<tr>
<td>Clozapine ≥ 6 months (n=55)</td>
<td>3.7 (1.8-7.5)*</td>
<td>2.8 (1.3-5.9)**</td>
</tr>
<tr>
<td>Sexy</td>
<td>1.0 (0.6-1.7)</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>0.8 (0.4-1.6)</td>
<td></td>
</tr>
<tr>
<td>Ethnicity</td>
<td>1.0 (0.6-1.6)</td>
<td></td>
</tr>
<tr>
<td>Age at onset of first psychosis</td>
<td>1.3 (0.6-2.7)</td>
<td></td>
</tr>
<tr>
<td>Duration of illness</td>
<td>1.4 (0.7-2.9)</td>
<td></td>
</tr>
<tr>
<td>Severity of psychosis measured with PANSS</td>
<td>1.6 (1.2-2.1)</td>
<td></td>
</tr>
</tbody>
</table>
positive symptom scale

*P<.001; **P=.007

Abbreviations: CI =Confidence interval, OCS= obsessive-compulsive symptoms, PANSS=Positive and Negative Syndrome Scale.

Within the group of patients with OCS the mean dosage of clozapine was 357.14 mg (standard deviation[SD] = 160.9); of olanzapine 14.2 mg (SD = 5.83); and of risperidone 5.4 mg (SD = 9.45). No differences were found in sex, age, ethnicity and age of onset of first psychosis between the different medication groups. The patients taking clozapine had a significant longer duration of illness ($\chi^2=18.9$, $p<.001$) (Table 3).

Within the group of patients with schizophrenia, we compared patients taking clozapine for more than 6 months (n=55) to patients taking clozapine for less than 6 months (n=17). No differences were found in sex, age, ethnicity, and daily dose of clozapine between these groups. Patients taking clozapine for 6 months or more were significantly younger when they developed schizophrenia ($Z=-3.73$, $p<.001$) and had a significant longer duration of illness ($Z=-3.24$, $p=.001$). Furthermore, the prevalence of OCS was significantly higher in patients taking clozapine for 6 months or longer versus patients taking clozapine for less than 6 months, 47.3% versus 11.8% ($\chi^2=6.89$, $p=.009$) (Table 4). No significant differences were found in OCS prevalence, age at onset, or duration of illness between patients taking olanzapine or risperidone for 6 months or longer or less than 6 months.

Since OCS is associated with more psychotic psychopathology and clozapine is used by patients with more severe psychotic illness, severity of the psychotic illness should be controlled for. Comparing
the prevalence of OCS between all 5 medication groups (no antipsychotics, risperidone, olanzapine, clozapine <6 months, clozapine ≥ 6 months) in logistic regression controlling for age, sex, ethnicity, age at onset of first psychosis, duration of illness, and score on the PANSS positive symptom scale showed a significant higher prevalence of OCS in the clozapine ≥ 6 months group (Table 5). The group not taking antipsychotics was used as reference group. None of the potential confounders proved significant.

Within the group of patients with a duration of illness longer than 4 years, comparing the prevalence of OCS between the different medication groups (clozapine, n=50, olanzapine, n=71, risperidone, n=51, patients not taking antipsychotics, n=53) a significant difference was found ($\chi^2= 9.64, p=.022$). Post-hoc tests showed that in the group with a duration of illness longer than 4 years patients taking clozapine reported significantly more OCS during the last week (48%), when compared to patients taking olanzapine (22.5%, $\chi^2=8.60, p=.003$) and patients not taking antipsychotics (26.4%, $\chi^2=5.15, p=.023$). This comparison showed a trend towards significance for patients with a duration of illness longer than 4 years taking risperidone (31.4%, $\chi^2=2.92, p=.088$).

Severity of OCS did not significantly differ between medication groups (including the group taking no antipsychotic medication): severity of obsessions ($F= 0.610, p=.610$), severity of compulsions ($F=1.69, p=.173$), resistance to obsessions and compulsions ($F=0.300, p=.825$), and total score ($F=0.146, p=.932$). Taking a cut-off point of 16 on the Y-BOCS, a standard criterion for OCD studies, severe OCS was not significantly differently distributed between the medication groups (including the group taking no antipsychotic medication) ($\chi^2=0. 567, p=.904$).

**DISCUSSION**

Patients had OCS more frequently (23.4%) than unaffected siblings (7.8%) or controls (4.9%). OCS prevalence in the control sample is relatively low compared to OCS prevalence reported in the general population, 21-25%. This difference is most likely due to differences in assessment. In community surveys most often the Diagnostic Interview Schedule (DIS) or its successor the Composite International Diagnostic Interview (CIDI), is used. This instrument is known to considerably overdiagnose OCS/OCD, up to fivefold. In our study presence of OCS was assessed with criteria according to the SCID-I/P and OCS was only considered present when the severity of OCS resulted in a positive Y-BOCS score. In consequence only clinical relevant symptoms were scored, potentially resulting in an underestimation of the prevalence of OCS, compared to assessment in which also minor OCS are included. Secondly, the DIS or CIDI cover lifetime prevalence or the last 12 months prior to assessment, whereas the Y-BOCS measures symptoms in the week before assessment, again leading to a stricter but more reliable assessment. It is possible that demographic differences between patient and control groups may have contributed to the difference in prevalence of OCS we found. Compared to patients, the control sample comprises significantly more females, with a significantly higher mean age and significantly more white
Obsessive-Compulsive Symptoms in patients with schizophrenia comparing treatment with Clozapine, Olanzapine, Risperidone and no antipsychotics: a naturalistic cross-sectional study of 543 patients

ethnicity. However, sex ratio of prevalence of OCS is estimated to be 1:1\textsuperscript{14} and logistic regression analysis showed no significant influence of sex, age, or ethnicity on the OCS prevalence.

For patients with schizophrenia, we found significant differences in age at onset of first psychosis and duration of illness between those with and those without OCS. It is known that patients with schizophrenia with an earlier age at onset have poorer outcome,\textsuperscript{65} furthermore several studies have shown the unfavorable effect of comorbid OCS on the course of schizophrenia.\textsuperscript{2,12,11} Therefore, a higher prevalence of OCS may be associated with a more severely illness, a younger age at onset of illness, and a longer illness duration.

Significantly more patients taking clozapine for 6 months or longer had OCS during the last week when compared to patients taking clozapine for less than 6 months, olanzapine, risperidone and patients not taking antipsychotic medication. This finding may be interpreted to support the hypothesis that clozapine contributes to the prevalence of OCS.\textsuperscript{22,36} However, clozapine is indicated for patients with treatment resistance. Therefore, the association between OCS and clozapine treatment may be explained by duration of illness, illness severity or treatment resistance. However when using logistic regression controlling for these confounders, with the patients group taking no antipsychotics as control group, clozapine use for 6 months or longer was still significantly associated with OCS prevalence.

No significant difference in prevalence of OCS between patients taking olanzapine or risperidone and patients not taking antipsychotic medication was found. Patients taking antipsychotics medication did not differ significantly in clinical characteristics or in diagnosis from patients not taking antipsychotics medication. This finding does not support the second part of the hypothesis, that patients taking atypical antipsychotics have a higher prevalence of OCS compared to patients not taking antipsychotic medication.

Within the group of patients with schizophrenia and OCS, a significant difference in duration of illness was seen between patients taking clozapine on one hand and olanzapine, risperidone no antipsychotic medication on the other hand. Again this finding may probably be explained by specific indication to take clozapine. No significant difference was found in severity of OCS between the different medication groups and the group not taking antipsychotic medication. This finding may imply that, for most patients, OCS related to treatment with clozapine is not severe and that there is no specific intervention needed.

Patients who were treated with clozapine for 6 months or longer had an earlier age of onset, a longer duration of illness and more frequently reported OCS in the week before assessment, compared to patients with a shorter treatment period. Maybe the effect of clozapine on OCS develops gradually. This possibly could imply that a substantial proportion of patients without OCS who took clozapine for less than 6 months may develop OCS during continued treatment. De Haan et al.\textsuperscript{44} found that severity of OCS was associated with duration of treatment with olanzapine. Another possible explanation for this finding is that patients taking clozapine for 6 months or longer are in fact, as mentioned above, the most
severely ill patients associated with this the most OCS comorbidity, although logistic regression analysis did not support this hypothesis.

The fact that we found no difference in prevalence between patients not taking antipsychotic medication and those taking risperidone, olanzapine, or clozapine for less than 6 months might indicate that the effect of antipsychotic medication is not substantial. The group of patients taking clozapine for 6 months or longer could represent a more severely ill group, with more OCS the result of a virulent psychopathological process instead of the result of treatment with clozapine, even though correcting for illness variables did not change the association between OCS and this patient group. On the other hand, more than 1 factor appears to be associated with OCS in schizophrenia. Many reports are published describing either the appearance of OCS after the start of antipsychotics or the disappearance. The fact that the sum of all the effects shows no significant effect compared to the group of patients not taking antipsychotics does not rule out the possibility that antipsychotic medication does influence OCS on an individual level.

One of the possible explanations of our findings could be the effect of clozapine on the serotonergic system. The serotonergic (5-HT) and the dopaminergic (D) system have been widely implicated in the pathophysiology of OCD.\textsuperscript{66} Theories explaining the role of antipsychotics in emergence or deterioration of OCS mostly address the 5-HT neurotransmission.\textsuperscript{14, 49, 67, 68} However, in addition to this fact, antipsychotic augmentation is an accepted treatment strategy for refractory OCD.\textsuperscript{18, 50}

This contradictory effect of atypical antipsychotics can be partially explained by their 5-HT \textsubscript{2} receptor occupancy: the emergence or deterioration of OCS is thought to be caused by the antagonism of 5-HT receptors, whereas therapeutic effects are thought to be caused by D\textsubscript{2} receptor blockade. Since positron emission tomography (PET) studies have shown that compared to typical antipsychotics, olanzapine and risperidone cause high 5-HT\textsubscript{2} receptor occupancy at low doses, whereas relatively high doses are needed to achieve dopamine D\textsubscript{2} receptor occupancy\textsuperscript{69, 70} it is possible that higher doses of these atypical antipsychotics might induce less OCS and have a larger treatment effect on OCS.\textsuperscript{71} Clozapine has a relatively low D\textsubscript{2} receptor occupancy and a fast dissociation rate. Therefore one might hypothesize that clozapine does not cause a sufficiently effective D\textsubscript{2} receptor blockade to be therapeutic in OCS and by its high 5-HT\textsubscript{2} receptor occupancy\textsuperscript{72} causes more emergence or deterioration of OCS, when compared to other antipsychotics. The pro-obsessional effects of clozapine are reported to be dose-related, with higher doses causing more OCS.\textsuperscript{16, 73} However, in this study no significant difference was found in mean daily dose of clozapine between the patients with and without OCS.

Another possible explanation for the reported contradictory effect of atypical antipsychotics (improving OCS and worsening OCS) could be that there are subgroups of patients with schizophrenia and OCS, with different 5-HT-related polymorphisms, that react differently to administration of antipsychotics in general and clozapine in particular.\textsuperscript{68, 49, 67, 68}
Several limitations of the current study should be mentioned. First, although our results are relatively robust and concur with former findings, our study was designed as a naturalistic cross-sectional study; therefore selection bias cannot be ruled out and our findings should be interpreted cautiously. We do indeed find that patients taking clozapine have a younger age at onset of first psychosis and a longer duration of illness, so we might have identified a subpopulation with a more severe course of illness, including more OCS comorbidity. Alas, we lack information regarding the onset of OCS in relation to the onset of schizophrenia or start of treatment with antipsychotic medication, which could have given us arguments favoring or opposing the hypothesis that specific atypical antipsychotics induce OCS. In the coming follow-up of the included patients, we will be able to study the association between medication switch or continuation and OCS prevalence and severity.

A randomised controlled double-blind, longitudinal study of the effect of different second-generation antipsychotics on the emergence or deterioration of OCS in patients with schizophrenia would provide more definite answers.

**CONCLUSION**

Treatment with clozapine in patients with schizophrenia or related disorders is associated with a higher prevalence of OCS, especially when patients have been taking clozapine for 6 months or longer. We cannot rule out the possibility that this association is related to illness characteristics. Patients treated with risperidone or olanzapine or without treatment with antipsychotic medication had comparable prevalence of OCS, significantly higher than the control sample.

**ACKNOWLEDGEMENTS**

We are grateful for the generosity of time and effort by the patients and all researchers who make this GROUP project possible.

The GROUP project was supported by a grant for Geestkracht programme of the Dutch Health Research Council (ZON-MW, grant number 10-000-1002) and matching funds from participating universities and mental health care organizations (Amsterdam: Academic psychiatric Centre of the Academic Medical Centre and the mental health institutions: GGZ Ingeest, Arkin, Dijk en Duin, Rivierduinen, Erasmus Medical Centre, GGZ Noord Holland Noord. Maastricht: Maastricht University Medical Centre and the mental health institutions: GGZ Eindhoven, GGZ Midden-Brabant, GGZ Oost-Brabant, GGZ Noord-Midden Limburg, Mondriaan Zorggroep, Prins Clauscentrum Sittard, RIAGG Roermond, Universitair Centrum Sint-Jozef Kortenberg, CAPRI University of Antwerp, PC Ziekeren Sint-Truiden, PZ Sancta
Chapter 5

Maria Sint-Truiden, GGZ Overpelt, OPZ Rekem. Groningen: University Medical Centre Groningen and the mental health institutions: Lentis, GGZ Friesland, GGZ Drenthe, Dimence, Mediant, GGZ De Grote Rivieren and Parnassia psycho-medical centre (The Hague). Utrecht: University Medical Centre Utrecht and the mental health institutions Altrecht, Symfora, Meerkanten, Riagg Amersfoort, en Delta).

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest that is directly relevant to the content of this article.
REFERENCES


44. de Haan L, Beuk N, Hoogenboom B, Dingemans P, Linszen D. Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or


55. Wing JK, Babor T, Brugha T et al. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry 1990;47(6):589-593.


